Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 7, 2026
Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC
View original at finance.yahoo.comMerck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC Third Phase 3 trial in Merck’s KANDLELIT clinical development program, whic…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
KRAS is the most frequently mutated oncogene in cancer, and the KRAS G12C mutation occurs in approximately 4% to 14% of all patients with lung cancer globally
80% confidenceMerck operates the largest immuno-oncology clinical research program with over 1,600 trials across multiple cancers
80% confidenceCombination of oral calderasib with subcutaneous KEYTRUDA QLEX will evaluate whether this chemotherapy-free combination requiring no intravenous access may help improve outcomes for patients with KRAS G12C-mutant NSCLC
80% confidence
Data points we hold from this source
| Merck & Co., Inc. · active clinical trials | 1600 trials |